Search Results - "Holdbrook, Fred K."

Body Weight Changes with β-Blocker Use: Results from GEMINI by Messerli, Franz H., MD, Bell, David S.H., MB, Fonseca, Vivian, MD, Katholi, Richard E., MD, McGill, Janet B., MD, Phillips, Robert A., MD, PhD, Raskin, Philip, MD, Wright, Jackson T., MD, PhD, Bangalore, Sripal, MD, Holdbrook, Fred K., PhD, Lukas, Mary Ann, MD, Anderson, Karen M., PhD, Bakris, George L., MD

“…Abstract Purpose Patients with type 2 diabetes are commonly overweight, which can contribute to poor cardiovascular outcomes. β-blockers may promote weight…”
Get full text

Lowering Blood Pressure With β‐Blockers in Combination With Other Renin‐Angiotensin System Blockers in Patients With Hypertension and Type 2 Diabetes: Results From the GEMINI Trial by Wright, Jackson T., Bakris, George L., Bell, David S. H., Fonseca, Vivian, Katholi, Richard E., McGill, Janet B., Messerli, Franz H., Phillips, Robert A., Raskin, Philip, Holdbrook, Fred K., Lukas, Mary Ann, Iyengar, Malini

“…The effects of β‐blockade in addition to more specific renin‐angiotensin system (RAS) blockers on blood pressure (BP) in patients with diabetes are described…”
Get full text

Switching treatment to cipaglucosidase alfa plus miglustat positively affects motor function and quality of life in patients with late-onset Pompe disease by Toscano, Antonio, Byrne, Barry J., Claeys, Kristl G., Diaz-Manera, Jordi, Dimachkie, Mazen M., Kishnani, Priya S., Kushlaf, Hani, Mozaffar, Tahseen, Roberts, Mark E., Hummel, Noemi, Holdbrook, Fred K., Shohet, Simon, Wasfi, Yasmine, Schoser, Benedikt

Get full text

Effect size analysis of cipaglucosidase alfa plus miglustat versus alglucosidase alfa in ERT-experienced adults with late-onset Pompe disease in PROPEL by Mozaffar, Tahseen, Bratkovic, Drago, Byrne, Barry J., Claeys, Kristl G., Diaz-Manera, Jordi, Dimachkie, Mazen M., Kishnani, Priya S., Kushlaf, Hani, Roberts, Mark E., Toscano, Antonio, Castelli, Jeffrey, Holdbrook, Fred K., Das, Sheela Sitaraman, Wasfi, Yasmine, Schoser, Benedikt

Get full text